1
|
Wang C, Bai C, Zhang Z, Zhou H, Gao H, Wang S, Yuan Y. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment. Cancer Gene Ther 2024:10.1038/s41417-024-00819-y. [PMID: 39122832 DOI: 10.1038/s41417-024-00819-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 07/27/2024] [Accepted: 07/31/2024] [Indexed: 08/12/2024]
Abstract
HER2-positive (HER2+) breast cancer accounts for 20-30% of all breast cancers. Although trastuzumab has significantly improved the survival of patients with HER2+ breast cancer, more than 70% of patients develop drug resistance within one year of treatment. Differential-gene-expression analysis of trastuzumab-sensitive and resistant HER2+ breast cancer cell lines from GSE15043 was performed to identify the biomarkers associated with trastuzumab resistance. Differential biomarker expression was confirmed in FFPE tissues collected from clinical HER2+ breast cancer tumor samples that were sensitive or resistant to trastuzumab treatment. UGT1A7, a member of the uronic acid transferase family, was associated with trastuzumab resistance. UGT1A7 expression was downregulated in trastuzumab-resistant tumor tissues and in a cell line that developed trastuzumab resistance (BT474TR). Overexpressing UGT1A7 in BT474TR restored their sensitivity to trastuzumab treatment, whereas downregulating UGT1A7 expression in parental cells led to trastuzumab resistance. Importantly, UGT1A7 localized to the endoplasmic reticulum and altered stress responses. Furthermore, downregulating UGT1A7 expression promoted epithelial-to-mesenchymal transition (EMT) by affecting TWIST, SNAIL, and GRP78 expression and the AMP-activated protein kinase signaling pathway, thus contributing to trastuzumab resistance. This study demonstrated the important role and novel mechanisms of UGT1A7 in tumor responses to trastuzumab. Low UGT1A7 expression plays an important role in EMT and contributes to trastuzumab resistance. UGT1A7 has the potential to be developed as a biomarker for identifying patients who are resistant to trastuzumab treatment.
Collapse
Affiliation(s)
- Cong Wang
- Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, China
| | - Chenguang Bai
- Department of Radiology, Jiangsu Cancer Hospital &Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Zhe Zhang
- Department of Pathology, Jiangsu Cancer Hospital &Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Hao Zhou
- Department of Chemotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Huanyao Gao
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - Siwei Wang
- Department of Thoracic Surgery, Jiangsu Cancer Hospital &Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Yuan Yuan
- Department of Chemotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
| |
Collapse
|
2
|
Mennillo E, Yang X, Weber AA, Maruo Y, Verreault M, Barbier O, Chen S, Tukey RH. Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model. Drug Metab Dispos 2022; 50:33-42. [PMID: 34697081 PMCID: PMC8969198 DOI: 10.1124/dmd.121.000644] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 10/19/2021] [Indexed: 01/03/2023] Open
Abstract
The human UDP-glucuronosyltransferases (UGTs) represent an important family of drug-metabolizing enzymes, with UGT1A1 targeting the conjugation and detoxification of many exogenous substances, including pharmaceutical drugs. In this study we generated humanized UGT1A1 mice expressing the human UGT1A1 gene in either liver (hUGT1A1HEP ) or intestine (hUGT1A1GI ), enabling experiments to examine tissue-specific properties of UGT1A1-specific glucuronidation. Hepatic and intestinal tissue-specific expression and function of UGT1A1 were demonstrated. Although the liver is considered a major organ for detoxification, intestinal UGT1A1 is an important contributor for drug clearance. Mice were challenged with irinotecan (CPT-11), a prodrug hydrolyzed by carboxylesterases to form the active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) and detoxified by UGT1A1. Humanized UGT1A1HEP mice that have no intestinal UGT1A1 displayed a greater lethality rate when exposed to CPT-11 than hUGT1A1GI mice. When exposed to a low dose of CPT-11 (10 mg/kg), hUGT1A1HEP mice displayed greater intestinal inflammatory (IL-1β and IL-6) insult in addition to p53-triggered apoptotic responses. In vitro studies with intestinal crypt organoids exposed to CPT-11 confirmed the results observed in vivo and indicated that CPT-11 impacts stemness, apoptosis, and endoplasmic reticulum (ER) stress in organoids deficient in UGT1A1. When we examined the induction of ER stress in organoids with thapsigargin, an inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase, apoptosis and the caspase surge that occurred in hUGT1A1HEP mice were blocked in hUGT1A1GI organoids. This study reveals the importance of intestinal UGT1A1 in preventing inflammation, apoptosis, and loss of stemness capacity upon systemic challenge with an important chemotherapeutic agent. SIGNIFICANCE STATEMENT: Hepatic and intestinal UGT1A1 play a key role in the metabolism and detoxification of endogenous and exogenous compounds. The use of tissue-specific humanized models expressing UGT1A1 in liver or intestine has confirmed the relevance of the intestinal tract in the detoxification of irinotecan. Mechanistic studies using intestinal organoids highlighted the importance of UGT1A1 in reducing inflammation, apoptosis, and loss of stemness. These new models provide valuable tools for studying tissue-specific glucuronidation of substances that are metabolized by human UGT1A1.
Collapse
Affiliation(s)
- Elvira Mennillo
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Xiaojing Yang
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Andre A Weber
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Yoshihiro Maruo
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Melanie Verreault
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Olivier Barbier
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Shujuan Chen
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| | - Robert H Tukey
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, California (E.M., X.Y., A.A.W., S.C., R.H.T.); Department of Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan (Y.M.); and Laboratory of Moléculaire Pharmacology, Centre de Recherche du CHU de Québec, Faculté of Pharmacie, Université Laval Québec, Québec, Canada (M.V., O.B.)
| |
Collapse
|
3
|
Hayal TB, DoĞan A, ŞİŞlİ HB, Kiratli B, Şahİn F. Ubiquitin-specific protease 7 downregulation suppresses breast cancer in vitro. ACTA ACUST UNITED AC 2020; 44:145-157. [PMID: 32922122 PMCID: PMC7478133 DOI: 10.3906/biy-1912-83] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Because breast cancer is complicated at the pathological, histological, clinical, and molecular levels, identification of new genetic targets against carcinogenic pathways is required to generate clinically relevant treatment options. In the current study, ubiquitin-specific protease 7 (USP7), which regulates various cellular pathways including Mdm2, p53, and NF–κB, was selected as a potential gene editing strategy for breast cancer in vitro. Anticancer activity of USP7 gene suppression has been evaluated through cell proliferation, gene expression, cell cycle, sphere dissemination, and cell migration analysis. Here, siRNA and shRNA strategies and an allosteric small-molecule inhibitor of USP7 were used to define potential anticancer activity against MCF7 and T47D human breast cancer cell lines. Both blockage of deubiquitination by p5091 and knockdown of USP7 reduced cell proliferation, cell migration, colony formation, and sphere dissemination for both MCF7 and T47D breast cancer cell lines. Restriction of USP7 activity strongly enhanced apoptotic gene expression and reduced metastatic ability of breast cancer cell lines. This study describes one potential molecular target for the suppression of breast cancer proliferation and metastasis. Identification of USP7 as a promising gene editing candidate might open up the possibility of new molecular drug research in targeting the ubiquitination pathway in cancer.
Collapse
Affiliation(s)
- Taha Bartu Hayal
- Yeditepe University, Department of Genetics and Bioengineering, Faculty of Engineering, İstanbul Turkey
| | - Ayşegül DoĞan
- Yeditepe University, Department of Genetics and Bioengineering, Faculty of Engineering, İstanbul Turkey
| | - Hatice Burcu ŞİŞlİ
- Yeditepe University, Department of Genetics and Bioengineering, Faculty of Engineering, İstanbul Turkey
| | - Binnur Kiratli
- Yeditepe University, Department of Genetics and Bioengineering, Faculty of Engineering, İstanbul Turkey
| | - Fikrettin Şahİn
- Yeditepe University, Department of Genetics and Bioengineering, Faculty of Engineering, İstanbul Turkey
| |
Collapse
|
4
|
Izumi K, Inoue S, Ide H, Fujita K, Mizushima T, Jiang G, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H. Uridine 5'diphospho-glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract. Int J Urol 2018; 25:429-435. [PMID: 29444544 DOI: 10.1111/iju.13528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Accepted: 12/25/2017] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To determine the expression status of uridine 5'diphospho-glucuronosyltransferase 1A, a major phase II drug metabolism enzyme, in upper urinary tract urothelial carcinoma, as well as to assess its prognostic significance. METHODS We immunohistochemically stained for uridine 5'diphospho-glucuronosyltransferase 1A in tissue microarray consisting of 99 upper urinary tract urothelial carcinoma samples and paired non-neoplastic urothelial tissues. We also assessed the effect of uridine 5'diphospho-glucuronosyltransferase 1A knockdown on urothelial cancer cell growth. RESULTS Uridine 5'diphospho-glucuronosyltransferase 1A was positive in 92.9% (27.3% weak [1+], 37.4% moderate [2+], 28.3% strong [3+]) of tumors, which was significantly (P < 0.001) lower than in benign urothelial tissues (98.8%; 3.5% 1+, 18.8% 2+, 76.4% 3+). All 37 (100%) non-muscle-invasive versus 55 (88.7%) of 62 muscle-invasive tumors (P = 0.043) were immunoreactive for uridine 5'diphospho-glucuronosyltransferase 1A. The rates of moderate-to-strong uridine 5'diphospho-glucuronosyltransferase 1A expression and its positivity were also strongly associated with the absence of concomitant carcinoma in situ (P = 0.034) and lymphovascular invasion (P = 0.016), respectively. However, there were no statistically significant associations between uridine 5'diphospho-glucuronosyltransferase 1A expression and tumor grade or pN/M status. Uridine 5'diphospho-glucuronosyltransferase 1A loss in M0 tumors was strongly associated with lower progression-free survival (P < 0.001) and cancer-specific survival (P < 0.001) rates. Multivariate analysis further identified a strong correlation of uridine 5'diphospho-glucuronosyltransferase 1A positivity with reduced cancer-specific mortality (hazard ratio 0.28, P = 0.018). Meanwhile, uridine 5'diphospho-glucuronosyltransferase 1A knockdown in urothelial cancer cells resulted in significant increases in their viability and migration. CONCLUSIONS These results suggest a preventive role of uridine 5'diphospho-glucuronosyltransferase 1A signals in the development and progression of upper urinary tract urothelial carcinoma. Loss of uridine 5'diphospho-glucuronosyltransferase 1A expression might serve as an independent predictor of poor prognosis in patients with upper urinary tract urothelial carcinoma.
Collapse
Affiliation(s)
- Koji Izumi
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.,Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan
| | - Satoshi Inoue
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.,James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.,Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Hiroki Ide
- Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Kazutoshi Fujita
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Taichi Mizushima
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.,James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.,Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Guiyang Jiang
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.,James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
| | - Seiji Yamaguchi
- Department of Urology, Osaka General Medical Center, Osaka, Japan
| | - Hiroaki Fushimi
- Department of Pathology, Osaka General Medical Center, Osaka, Japan
| | - Norio Nonomura
- Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Hiroshi Miyamoto
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.,James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA.,Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.,Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
| |
Collapse
|
5
|
Fujiwara R, Yoda E, Tukey RH. Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans. Drug Metab Pharmacokinet 2017; 33:9-16. [PMID: 29079228 DOI: 10.1016/j.dmpk.2017.10.002] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 09/05/2017] [Accepted: 10/03/2017] [Indexed: 12/11/2022]
Abstract
More than 20% of clinically used drugs are glucuronidated by a microsomal enzyme UDP-glucuronosyltransferase (UGT). Inhibition or induction of UGT can result in an increase or decrease in blood drug concentration. To avoid drug-drug interactions and adverse drug reactions in individuals, therefore, it is important to understand whether UGTs are involved in metabolism of drugs and drug candidates. While most of glucuronides are inactive metabolites, acyl-glucuronides that are formed from compounds with a carboxylic acid group can be highly toxic. Animals such as mice and rats are widely used to predict drug metabolism and drug-induced toxicity in humans. However, there are marked species differences in the expression and function of drug-metabolizing enzymes including UGTs. To overcome the species differences, mice in which certain drug-metabolizing enzymes are humanized have been recently developed. Humanized UGT1 (hUGT1) mice were created in 2010 by crossing Ugt1-null mice with human UGT1 transgenic mice in a C57BL/6 background. hUGT1 mice can be promising tools to predict human drug glucuronidation and acyl-glucuronide-associated toxicity. In this review article, studies of drug metabolism and toxicity in the hUGT1 mice are summarized. We further discuss research and strategic directions to advance the understanding of drug glucuronidation in humans.
Collapse
Affiliation(s)
- Ryoichi Fujiwara
- Department of Pharmaceutics, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
| | - Emiko Yoda
- Division of Health Chemistry, Department of Healthcare and Regulatory Sciences, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
| | - Robert H Tukey
- Laboratory of Environmental Toxicology, Department of Pharmacology, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|
6
|
Fujiwara R, Yokoi T, Nakajima M. Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases. Front Pharmacol 2016; 7:388. [PMID: 27822186 PMCID: PMC5075577 DOI: 10.3389/fphar.2016.00388] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Accepted: 10/05/2016] [Indexed: 12/11/2022] Open
Abstract
Mammalian UDP-glucuronosyltransferases (UGTs) catalyze the transfer of glucuronic acid from UDP-glucuronic acid to various xenobiotics and endobiotics. Since UGTs comprise rate-limiting enzymes for metabolism of various compounds, co-administration of UGT-inhibiting drugs and genetic deficiency of UGT genes can cause an increased blood concentration of these compounds. During the last few decades, extensive efforts have been made to advance the understanding of gene structure, function, substrate specificity, and inhibition/induction properties of UGTs. However, molecular mechanisms and physiological importance of the oligomerization and protein–protein interactions of UGTs are still largely unknown. While three-dimensional structures of human UGTs can be useful to reveal the details of oligomerization and protein–protein interactions of UGTs, little is known about the protein structures of human UGTs due to the difficulty in solving crystal structures of membrane-bound proteins. Meanwhile, soluble forms of plant and bacterial UGTs as well as a partial domain of human UGT2B7 have been crystallized and enabled us to predict three-dimensional structures of human UGTs using a homology-modeling technique. The homology-modeled structures of human UGTs do not only provide the detailed information about substrate binding or substrate specificity in human UGTs, but also contribute with unique knowledge on oligomerization and protein–protein interactions of UGTs. Furthermore, various in vitro approaches indicate that UGT-mediated glucuronidation is involved in cell death, apoptosis, and oxidative stress as well. In the present review article, recent understandings of UGT protein structures as well as physiological importance of the oligomerization and protein–protein interactions of human UGTs are discussed.
Collapse
Affiliation(s)
- Ryoichi Fujiwara
- Department of Pharmaceutics, School of Pharmacy, Kitasato University Tokyo, Japan
| | - Tsuyoshi Yokoi
- Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of Medicine Nagoya, Japan
| | - Miki Nakajima
- Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University Kanazawa, Japan
| |
Collapse
|